With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens ...

The R-CHOP chemotherapy regimen -- rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone -- has been the standard first-line therapy in diffuse large B-cell ...

Please provide your email address to receive an email when new articles are posted on . An experimental first-line regimen significantly extended PFS compared with standard of care for patients with ...

Credit: Genentech. The sBLA is supported by data from the phase 3 trial that compared polatuzumab vedotin plus R-CHP to standard of care R-CHOP. The Food and Drug Administration (FDA) has accepted the ...

Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma ...

The FDA's Oncologic Drugs Advisory Committee (ODAC) will meet Thursday to consider whether results from the POLARIX trial support a favorable benefit-risk assessment for adult patients with previously ...

First-in-class antibody-drug conjugate that specifically targets CD79b and destroys B cells through the delivery of an anti-cancer agent ii,iii DLBCL is an aggressive and fast-growing form of ...

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age Safety and efficacy of polatuzumab vedotin with ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...

The appraisal committee considered evidence submitted by Roche, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...

Please provide your email address to receive an email when new articles are posted on . The addition of polatuzumab vedotin to chemotherapy significantly extended PFS compared with standard first-line ...